CRESPIATICO, ILARIA
 Distribuzione geografica
Continente #
NA - Nord America 869
EU - Europa 706
AS - Asia 99
OC - Oceania 4
AF - Africa 1
SA - Sud America 1
Totale 1.680
Nazione #
US - Stati Uniti d'America 864
IT - Italia 301
DE - Germania 132
IE - Irlanda 105
SE - Svezia 44
CN - Cina 41
FR - Francia 38
GB - Regno Unito 37
HK - Hong Kong 32
FI - Finlandia 12
IN - India 9
BE - Belgio 7
VN - Vietnam 6
CA - Canada 5
PL - Polonia 5
AU - Australia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
SG - Singapore 4
NL - Olanda 3
NO - Norvegia 3
RO - Romania 3
TR - Turchia 3
ES - Italia 2
JP - Giappone 2
UA - Ucraina 2
BG - Bulgaria 1
BR - Brasile 1
CH - Svizzera 1
GR - Grecia 1
IQ - Iraq 1
IR - Iran 1
MU - Mauritius 1
RU - Federazione Russa 1
Totale 1.680
Città #
Ann Arbor 350
Dublin 105
Frankfurt am Main 104
Milan 96
Fairfield 68
Wilmington 59
Chandler 54
Ashburn 46
New York 42
Hong Kong 32
Houston 32
Seattle 32
Woodbridge 25
Paris 21
Cambridge 19
Monza 14
Shanghai 14
Princeton 12
Slough 11
Altamura 9
Carate Brianza 9
Helsinki 9
Los Angeles 9
Florence 7
Rome 7
Beijing 6
Desio 6
Lawrence 6
Lodi 6
Dong Ket 5
Grafing 5
Guangzhou 5
Meda 5
Munich 5
Stockholm 5
Washington 5
Boardman 4
Brno 4
Cagliari 4
Dearborn 4
Duncan 4
Fremont 4
Leuven 4
Lodz 4
London 4
Perth 4
Sesto San Giovanni 4
Turin 4
Arese 3
Bonndorf 3
Brussels 3
Cesena 3
Cinisello Balsamo 3
Corbetta 3
Fontaniva 3
Genoa 3
Kilburn 3
Kocaeli 3
Lappeenranta 3
Nanjing 3
Rho 3
San Francisco 3
Shenyang 3
Usmate Velate 3
Agrate Brianza 2
Barcelona 2
Bradford 2
Cassolnovo 2
Cesano Maderno 2
Como 2
Cruseilles 2
Dortmund 2
Essen 2
Hebei 2
Hyderabad 2
Iasi 2
Jacksonville 2
Lissone 2
Milton Keynes 2
Monmouth Junction 2
Muggiò 2
Nanchang 2
Naples 2
Nichelino 2
Nova Milanese 2
Oslo 2
Ottawa 2
Pavia 2
Pignataro Maggiore 2
Pune 2
Randazzo 2
Redmond 2
San Diego 2
Schweinfurt 2
Sumirago 2
Tianjin 2
Toronto 2
Trento 2
Treviglio 2
Veniano 2
Totale 1.413
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 367
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 248
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 229
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 214
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 196
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 109
Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint 108
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 64
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 53
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 40
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 39
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 37
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 33
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 28
Idiopathic erythrocytosis: a germline disease? 20
Totale 1.785
Categoria #
all - tutte 5.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.014


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 0 0 14 8
2019/2020215 7 9 8 7 10 41 34 19 23 36 14 7
2020/2021439 12 4 22 27 23 25 112 60 39 35 45 35
2021/2022209 32 31 29 17 22 17 4 10 9 10 14 14
2022/2023320 24 71 34 16 32 36 22 13 23 8 17 24
2023/2024580 100 25 27 41 44 109 101 32 50 49 2 0
Totale 1.785